ATE267836T1 - Purinderivate - Google Patents

Purinderivate

Info

Publication number: ATE267836T1
Authority: AT; Austria
Prior art keywords: purine derivatives; purine; derivatives
Prior art date: 2000-06-27

Application number

AT01938490T

Other languages

English (en)

Inventor

Simon John Mantell

Sandra Marina Monaghan

Peter Thomas Stephenson

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-27

Filing date

2001-06-14

Publication date

2004-06-15

2001-06-14 Application filed by Pfizer filed Critical Pfizer

2004-06-15 Application granted granted Critical

2004-06-15 Publication of ATE267836T1 publication Critical patent/ATE267836T1/de

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Reproductive Health (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Gynecology & Obstetrics (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Pregnancy & Childbirth (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Obesity (AREA)

AT01938490T 2000-06-27 2001-06-14 Purinderivate ATE267836T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0015727.1A GB0015727D0 (en)	2000-06-27	2000-06-27	Purine derivatives
PCT/IB2001/001064 WO2002000676A1 (en)	2000-06-27	2001-06-14	Purine derivatives

Publications (1)

Publication Number	Publication Date
ATE267836T1 true ATE267836T1 (de)	2004-06-15

Family

ID=9894500

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT01938490T ATE267836T1 (de)	2000-06-27	2001-06-14	Purinderivate

Country Status (42)

Country	Link
EP (1)	EP1296996B1 (de)
JP (1)	JP2004501929A (de)
KR (1)	KR20030036248A (de)
CN (1)	CN1432020A (de)
AP (1)	AP1372A (de)
AR (1)	AR028759A1 (de)
AT (1)	ATE267836T1 (de)
AU (1)	AU2001264164A1 (de)
BG (1)	BG107171A (de)
BR (1)	BR0111912A (de)
CA (1)	CA2412564C (de)
CZ (1)	CZ20023992A3 (de)
DE (1)	DE60103537T2 (de)
DK (1)	DK1296996T3 (de)
DO (1)	DOP2001000195A (de)
EA (1)	EA200201291A1 (de)
EC (1)	ECSP024396A (de)
EE (1)	EE200200712A (de)
ES (1)	ES2220775T3 (de)
GB (1)	GB0015727D0 (de)
GT (1)	GT200100119A (de)
HR (1)	HRP20020995A2 (de)
HU (1)	HUP0301389A3 (de)
IL (1)	IL152529A0 (de)
IS (1)	IS6580A (de)
MA (1)	MA26918A1 (de)
MX (1)	MXPA03000078A (de)
NO (1)	NO20025975L (de)
NZ (1)	NZ521867A (de)
OA (1)	OA12294A (de)
PA (1)	PA8521001A1 (de)
PE (1)	PE20020213A1 (de)
PL (1)	PL361384A1 (de)
PT (1)	PT1296996E (de)
SI (1)	SI1296996T1 (de)
SK (1)	SK17332002A3 (de)
SV (1)	SV2002000507A (de)
TN (1)	TNSN01096A1 (de)
TR (1)	TR200401622T4 (de)
UY (1)	UY26797A1 (de)
WO (1)	WO2002000676A1 (de)
ZA (1)	ZA200209557B (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE60215028T2 (de)	2001-08-14	2007-03-15	Eli Lilly And Co., Indianapolis	Indol derivate als beta-3-adrenerge agonisten zur behandlung von typ 2 diabetes
SE0201980D0 (sv) *	2002-06-24	2002-06-24	Astrazeneca Ab	Novel compounds
AU2003275257A1 (en)	2002-09-26	2004-04-19	Bristol-Myers Squibb Company	N-substituted heterocyclic amines as modulators of chemokine receptor activity
TW200519106A (en)	2003-05-02	2005-06-16	Novartis Ag	Organic compounds
GB0401334D0 (en)	2004-01-21	2004-02-25	Novartis Ag	Organic compounds
GB0411056D0 (en)	2004-05-18	2004-06-23	Novartis Ag	Organic compounds
AR049384A1 (es)	2004-05-24	2006-07-26	Glaxo Group Ltd	Derivados de purina
US7863253B2 (en) *	2004-09-20	2011-01-04	Inotek Pharmaceuticals Corporation	Purine Derivatives and methods of use thereof
GB0424284D0 (en)	2004-11-02	2004-12-01	Novartis Ag	Organic compounds
GB0426164D0 (en)	2004-11-29	2004-12-29	Novartis Ag	Organic compounds
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
GB0514809D0 (en)	2005-07-19	2005-08-24	Glaxo Group Ltd	Compounds
KR20130020850A (ko)	2005-10-21	2013-02-28	노파르티스 아게	Ｉｌ-13에 대항한 인간 항체 및 치료적 용도
GB0601951D0 (en)	2006-01-31	2006-03-15	Novartis Ag	Organic compounds
BRPI0710573A2 (pt) *	2006-04-21	2012-02-28	Novartis Ag	compostos orgánicos, usos e processos para a preparação dos referidos compostos, bem como composição farmacêutica compreendendo os mesmos
US7589076B2 (en) *	2006-05-18	2009-09-15	Pgx Health, Llc	Substituted aryl piperidinylalkynyladenosines as A2AR agonists
CA2664378A1 (en)	2006-09-29	2008-04-03	Novartis Ag	Pyrazolopyrimidines as pi3k lipid kinase inhibitors
KR20090075714A (ko)	2006-10-30	2009-07-08	노파르티스 아게	소염제로서의 헤테로시클릭 화합물
US7897737B2 (en)	2006-12-05	2011-03-01	Lasergen, Inc.	3′-OH unblocked, nucleotides and nucleosides, base modified with photocleavable, terminating groups and methods for their use in DNA sequencing
US8431578B2 (en)	2008-01-11	2013-04-30	Novartis Ag	Organic compounds
AU2009257369B2 (en) *	2008-06-11	2015-03-26	Agilent Technologies, Inc.	Nucleotides and nucleosides and methods for their use in DNA sequencing
PL2391366T3 (pl)	2009-01-29	2013-04-30	Novartis Ag	Podstawione benzimidazole do leczenia gwiaździaków
US8389526B2 (en)	2009-08-07	2013-03-05	Novartis Ag	3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
MX2012001838A (es)	2009-08-12	2012-02-29	Novartis Ag	Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
US9085560B2 (en)	2009-08-17	2015-07-21	Intellikine, Inc.	Heterocyclic compounds and uses thereof
WO2012034095A1 (en)	2010-09-09	2012-03-15	Irm Llc	Compounds and compositions as trk inhibitors
UY33597A (es)	2010-09-09	2012-04-30	Irm Llc	Compuestos y composiciones como inhibidores de la trk
EP2673277A1 (de)	2011-02-10	2013-12-18	Novartis AG	[1, 2, 4] triazolo [4, 3]pyridazinverbindungen als inhibitoren dec-met-tyrosinkinase
JP5808826B2 (ja)	2011-02-23	2015-11-10	インテリカイン，エルエルシー	複素環化合物およびその使用
JP5959541B2 (ja)	2011-02-25	2016-08-02	ノバルティスアーゲー	Ｔｒｋ阻害剤としてのピラゾロ［１，５−ａ］ピリジン
AU2012310168B2 (en)	2011-09-15	2015-07-16	Novartis Ag	6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
US20130209543A1 (en)	2011-11-23	2013-08-15	Intellikine Llc	Enhanced treatment regimens using mtor inhibitors
RU2660354C2 (ru)	2012-04-03	2018-07-05	Новартис Аг	Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение
CN105246482A (zh)	2013-03-15	2016-01-13	因特利凯有限责任公司	激酶抑制剂的组合及其用途
TW201605450A (zh)	2013-12-03	2016-02-16	諾華公司	Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
WO2016011658A1 (en)	2014-07-25	2016-01-28	Novartis Ag	Combination therapy
RU2695230C2 (ru)	2014-07-31	2019-07-22	Новартис Аг	Сочетанная терапия
TW202140550A (zh)	2020-01-29	2021-11-01	瑞士商諾華公司	使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1988003147A1 (en) *	1986-10-31	1988-05-05	Warner-Lambert Company	Selected n6-substituted adenosines having selective a2 binding activity
IL107101A0 (en) *	1992-09-30	1993-12-28	Merrell Dow Pharma	2-substituted adenosines with a-2 receptor affinity
GB9723590D0 (en) *	1997-11-08	1998-01-07	Glaxo Group Ltd	Chemical compounds
EP1044004A1 (de) *	1998-01-08	2000-10-18	The University Of Virginia Patent Foundation	A2a adenosin rezeptor agonisten in kombination mit typ iv phosphodiesterase inhibitoren
CA2347512C (en) *	1998-10-16	2005-12-06	Pfizer Inc.	Adenine derivatives
GB9913932D0 (en) *	1999-06-15	1999-08-18	Pfizer Ltd	Purine derivatives
GB9924363D0 (en) *	1999-10-14	1999-12-15	Pfizer Central Res	Purine derivatives
GB9924361D0 (en) *	1999-10-14	1999-12-15	Pfizer Ltd	Purine derivatives

2000
- 2000-06-27 GB GBGB0015727.1A patent/GB0015727D0/en not_active Ceased
2001
- 2001-06-14 WO PCT/IB2001/001064 patent/WO2002000676A1/en not_active Application Discontinuation
- 2001-06-14 HU HU0301389A patent/HUP0301389A3/hu unknown
- 2001-06-14 EP EP01938490A patent/EP1296996B1/de not_active Expired - Lifetime
- 2001-06-14 EE EEP200200712A patent/EE200200712A/xx unknown
- 2001-06-14 SI SI200130136T patent/SI1296996T1/xx unknown
- 2001-06-14 IL IL15252901A patent/IL152529A0/xx unknown
- 2001-06-14 TR TR2004/01622T patent/TR200401622T4/xx unknown
- 2001-06-14 AT AT01938490T patent/ATE267836T1/de not_active IP Right Cessation
- 2001-06-14 MX MXPA03000078A patent/MXPA03000078A/es active IP Right Grant
- 2001-06-14 NZ NZ521867A patent/NZ521867A/en unknown
- 2001-06-14 BR BR0111912-5A patent/BR0111912A/pt not_active IP Right Cessation
- 2001-06-14 DK DK01938490T patent/DK1296996T3/da active
- 2001-06-14 KR KR1020027017723A patent/KR20030036248A/ko not_active Application Discontinuation
- 2001-06-14 CZ CZ20023992A patent/CZ20023992A3/cs unknown
- 2001-06-14 OA OA1200200387A patent/OA12294A/en unknown
- 2001-06-14 CN CN01810621A patent/CN1432020A/zh active Pending
- 2001-06-14 EA EA200201291A patent/EA200201291A1/ru unknown
- 2001-06-14 JP JP2002505798A patent/JP2004501929A/ja active Pending
- 2001-06-14 CA CA002412564A patent/CA2412564C/en not_active Expired - Fee Related
- 2001-06-14 AU AU2001264164A patent/AU2001264164A1/en not_active Abandoned
- 2001-06-14 DE DE60103537T patent/DE60103537T2/de not_active Expired - Fee Related
- 2001-06-14 PT PT01938490T patent/PT1296996E/pt unknown
- 2001-06-14 ES ES01938490T patent/ES2220775T3/es not_active Expired - Lifetime
- 2001-06-14 SK SK1733-2002A patent/SK17332002A3/sk unknown
- 2001-06-14 PL PL36138401A patent/PL361384A1/xx not_active Application Discontinuation
- 2001-06-21 GT GT200100119A patent/GT200100119A/es unknown
- 2001-06-21 AP APAP/P/2001/002193A patent/AP1372A/en active
- 2001-06-22 DO DO2001000195A patent/DOP2001000195A/es unknown
- 2001-06-25 PE PE2001000615A patent/PE20020213A1/es not_active Application Discontinuation
- 2001-06-25 PA PA20018521001A patent/PA8521001A1/es unknown
- 2001-06-26 AR ARP010103038A patent/AR028759A1/es unknown
- 2001-06-26 SV SV2001000507A patent/SV2002000507A/es not_active Application Discontinuation
- 2001-06-26 TN TNTNSN01096A patent/TNSN01096A1/fr unknown
- 2001-06-26 UY UY26797A patent/UY26797A1/es not_active Application Discontinuation
2002
- 2002-10-07 BG BG107171A patent/BG107171A/xx unknown
- 2002-10-10 IS IS6580A patent/IS6580A/is unknown
- 2002-11-25 ZA ZA200209557A patent/ZA200209557B/en unknown
- 2002-12-12 NO NO20025975A patent/NO20025975L/no not_active Application Discontinuation
- 2002-12-12 HR HR20020995A patent/HRP20020995A2/hr not_active Application Discontinuation
- 2002-12-19 EC EC2002004396A patent/ECSP024396A/es unknown
- 2002-12-20 MA MA26970A patent/MA26918A1/fr unknown

Also Published As

Publication number	Publication date
EP1296996A1 (de)	2003-04-02
PE20020213A1 (es)	2002-03-19
DE60103537D1 (de)	2004-07-01
EE200200712A (et)	2004-06-15
CZ20023992A3 (cs)	2003-12-17
IS6580A (is)	2002-10-10
HUP0301389A2 (hu)	2003-08-28
KR20030036248A (ko)	2003-05-09
EP1296996B1 (de)	2004-05-26
CN1432020A (zh)	2003-07-23
SV2002000507A (es)	2002-07-03
DOP2001000195A (es)	2002-05-15
PT1296996E (pt)	2004-08-31
TR200401622T4 (tr)	2004-08-23
SK17332002A3 (sk)	2004-03-02
DK1296996T3 (da)	2004-08-16
PA8521001A1 (es)	2002-04-25
DE60103537T2 (de)	2005-07-07
MA26918A1 (fr)	2004-12-20
ES2220775T3 (es)	2004-12-16
EA200201291A1 (ru)	2003-04-24
ECSP024396A (es)	2003-02-06
ZA200209557B (en)	2003-12-02
AU2001264164A1 (en)	2002-01-08
UY26797A1 (es)	2002-01-31
PL361384A1 (en)	2004-10-04
WO2002000676A1 (en)	2002-01-03
BG107171A (en)	2003-07-31
AP1372A (en)	2005-02-21
GB0015727D0 (en)	2000-08-16
SI1296996T1 (en)	2004-10-31
OA12294A (en)	2003-11-14
NO20025975D0 (no)	2002-12-12
BR0111912A (pt)	2003-05-13
NZ521867A (en)	2004-04-30
MXPA03000078A (es)	2003-08-19
HRP20020995A2 (en)	2005-02-28
JP2004501929A (ja)	2004-01-22
CA2412564A1 (en)	2002-01-03
HUP0301389A3 (en)	2005-02-28
NO20025975L (no)	2002-12-12
AR028759A1 (es)	2003-05-21
CA2412564C (en)	2007-10-02
TNSN01096A1 (fr)	2005-11-10
GT200100119A (es)	2002-01-31
IL152529A0 (en)	2003-05-29

Publication	Publication Date	Title
ATE325807T1 (de)	2006-06-15	Purinderivate
DE60103537D1 (de)	2004-07-01	Purinderivate
ATE431356T1 (de)	2009-05-15	2-aminocarbonyl-9h-purinderivative
DE60116260D1 (de)	2006-02-02	Antivirale azaindolderivate
ATE321065T1 (de)	2006-04-15	Purin-derivate
DE60002356D1 (de)	2003-05-28	Purin-derivate
IS6196A (is)	2001-12-11	Púrín afleiður
ATE372988T1 (de)	2007-09-15	Pyrimidin-derivate
ATE298332T1 (de)	2005-07-15	Decahydro-isochinolinderivate
DK1280809T3 (da)	2005-11-07	Antitumorecteinascidinderivater
AR028282A1 (es)	2003-04-30	Derivados de aminofenil pirimidona
DK1322593T3 (da)	2004-10-11	O-substituerede-6-methyl-tramadol-derivater
ATE280752T1 (de)	2004-11-15	Aminomethyl-phenyl-cyclohexanonderivate
ATE374776T1 (de)	2007-10-15	Pyrrolotriazolopyrimidinonderivate
NO20024393D0 (no)	2002-09-13	2-fenylpyran-4-on-derivater

Legal Events

Date	Code	Title	Description
2005-01-15	UEP	Publication of translation of european patent specification	Ref document number: 1296996 Country of ref document: EP
2006-03-15	REN	Ceased due to non-payment of the annual fee

Date

Code

Title

Description

2005-01-15

UEP

Publication of translation of european patent specification

Ref document number: 1296996

Country of ref document: EP

2006-03-15

REN

Ceased due to non-payment of the annual fee